Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12379309 | 0.87 | PPARG (0.39) | PPARGPPARASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL12361260 | 0.84 | BRD4 (0.46) | SMN1; SMN2DRD2DRD4DRD3L3MBTL1 | |
| SCHEMBL1105494 | 0.84 | ANPEP (0.44) | PPARGSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL404699 | 0.80 | PPARG (0.46) | PPARGLMNAMAPK1ALDH1A1 | |
| SCHEMBL1109433 | 0.80 | HDAC1 (0.46) | PPARGSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL1109156 | 0.78 | PPARG (0.39) | PPARGPPARASMN1; SMN2DRD2DRD4 | |
| SCHEMBL14400807 | 0.77 | CYP1A2 (0.47) | PPARGSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1109349 | 0.77 | CYP1A2 (0.47) | PPARGSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1109158 | 0.77 | PPARG (0.47) | PPARGPPARAHRH3NPC1RAB9A | |
| SCHEMBL9925890 | 0.76 | MAPK8 (0.40) | SMN1; SMN2DRD2DRD4DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | PPARG 1875/4885PPARA 1684/4885SMN1; SMN2 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.